Nasdaq

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

SAN DIEGO, Feb. 24, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
Nasdaq

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with ...

SAN DIEGO, Jan. 2, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
FierceBiotech

Regulus Expands Development of RG-101 through Clinical Trial Collaboration with GSK

LA JOLLA, Calif., Nov. 3, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs ...
FierceBiotech

RG-125 (AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 for the Treatment of NASH in Patients with Type 2 Diabetes/Pre-Diabetes, Selected as Clinical Candidate by ...

-RG-125 (AZD4076) is Regulus' 3rd Clinical Candidate, Achieving Key 'Clinical Map Initiative' Goal for 2015- LA JOLLA, Calif., April 7, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a ...
Seeking Alpha

The Read On Regulus Therapeutics

Today's in-depth piece is on microcap name that came as a suggestion for research from a Seeking Alpha follower. A full investment analysis follows below. The company seeks to develop and ...